Company intelligence / Profile preview

Naurex

Ownership: Private
Development stage: Phase 3

Overview

Naurex developed two lead compounds—rapastinel (GLYX-13) and NRX‑1074—that demonstrated rapid onset of action and robust efficacy in Phase 2 studies for major depressive disorder. The company’s approach focused on novel NMDA modulation to address unmet needs in mental health. The clinical results were promising enough to prompt Allergan’s $560 million acquisition in 2015.

Therapeutic areas: PsychiatryNeurology
Modalities: small molecules
Industry: Biotech

Drug pipeline

2 assets

rapastinel

Phase 3

Indications: Major depressive disorder, Treatment-resistant depression

1 more asset in the full pipeline.

Request access →

Partnerships

Research collaboration with Allergan post-acquisition via spin-out Aptinyx for discovery/preclinical development of NMDA modulatorsNorthwestern University academic origins/collaboration

Beyond the preview

Go deeper on Naurex.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Naurex.

Explore the full profile